VeritaScience

Executive Summary

VeritaScience is a newly formed biotechnology company established in January 2024 through a strategic alliance between Washington University in St. Louis (WashU) and Deerfield Management. The company is designed to accelerate the translation of academic biomedical research into next-generation therapeutics, with an initial focus on oncology and immunology. By leveraging WashU's scientific expertise and Deerfield's capital and development resources, VeritaScience aims to bridge the gap between early-stage academic discoveries and clinical development. The company operates as a funding and development vehicle, targeting novel therapies that address high unmet medical needs. While still in its early stages, VeritaScience's unique structure and strong backing position it to rapidly advance a pipeline of innovative drug candidates derived from WashU's research. The company's success will depend on its ability to select compelling targets, efficiently execute preclinical and clinical development, and ultimately deliver transformative treatments to patients.

Upcoming Catalysts (preview)

• Q2 2027Announcement of Lead Development Programs60% success
• Q4 2026Series A Funding Round or Additional Strategic Partnership70% success
• Q1 2028First Preclinical Data or IND Filing for Lead Asset50% success